Evidence map›Paper›PMID 30806518›Full record

GuidelineCephalalgia : an international journal of headache2019

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition.

Hans-Christoph Diener, Cristina Tassorelli, David W Dodick, Stephen D Silberstein, Richard B Lipton, Messoud Ashina, Werner J Becker, Michel D Ferrari, Peter J Goadsby, Patricia Pozo-Rosich and 3 more

6 registry-linked trialsOpen access · hybridAbstract readGuideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Cephalalgia : an international journal of headache, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 96 papers, 19 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 19 pooled it
19.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03951649 phase4completednot on this mapstarted 2020, after this paper: background citation

Acute Headache Treatment in Pregnancy: Improvement in Pain Scores With Occipital Nerve Block vs PO Acetaminophen With Caffeine A Randomized Controlled Trial

TypeinterventionalSponsorUniversity of Alabama at BirminghamRan2020 to 2022Enrolled62ConditionsHeadache, Pregnancy Related, Occipital Nerve BlockArmsOccipital Nerve Block
NCT04473976 completednot on this map

Plasma Levels of CGRP and Expression of Specific microRNAs in Blood Cells of Episodic and Chronic Migraine Subjects: Toward the Identification of a Panel of Peripheral Biomarkers of Migraine?

TypeobservationalSponsorIRCCS National Neurological Institute "C. Mondino" FoundationRan2017 to 2019Enrolled55ConditionsMigraine
NCT04491474 phase4completednot on this mapstarted 2020, after this paper: background citation

Comparison of Great Occipital Nerve and Supraorbital Nerve Blockade Treatment Methods Individually and in Combination With Placebo in an Acute Migraine Attack in the Emergency Department, a Prospective, Double Blind, Randomized Controlled Study

TypeinterventionalSponsorDr. Lutfi Kirdar Kartal Training and Research HospitalRan2020 to 2021Enrolled128ConditionsMigraine DisordersArmsLidocaine Hydrochloride, Placebo
NCT04799015 phase4completednot on this mapstarted 2021, after this paper: background citation

A Randomized Study of Dexamethasone as Adjuvant Therapy for Acute Post-traumatic Headache

TypeinterventionalSponsorMontefiore Medical CenterRan2021 to 2024Enrolled162ConditionsPost-Traumatic HeadacheArmsDexamethasone, Metoclopramide 10mg
NCT06267664 unknown statusnot on this mapstarted 2023, after this paper: background citation

Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP): an International Prospective Multicentric Cohort Study

Typeobservational_patient_registrySponsorHospital Clínico Universitario de ValladolidRan2023 to 2024Enrolled1,500ConditionsMigraine, Migraine Disorders, Migraine With Aura, Headache DisordersArmsPatients with migraine treated with triptans, Lasmiditan or Gepants
NCT07040813 phase3recruitingnot on this mapstarted 2025, after this paper: background citation

A Randomized Placebo-controlled Double-blind Phase III Trial to Investigate the Reduction of Monthly Migraine Days (MMDs) Over 12 Weeks of Treatment With CGRP mAbs and Onabotulinumtoxin A Intramuscularly Compared With CGRP mAbs and Placebo in Chronic Migraine

TypeinterventionalSponsorOslo University HospitalRan2025 to 2029Enrolled450ConditionsMigraine, Chronic Migraine HeadacheArmsCGRP mAbs and onabotulinumtoxin A, CGRP mAbs and placebo
3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 19 syntheses or guidelines pooled it, 227 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Headaches in adults in supplementary health: management.Revista da Associacao Medica Brasileira (1992) · 2024
    Guideline
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Non-invasive neuromodulation in the acute treatment of migraine: a systematic review and meta-analysis of randomized controlled trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Trial

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 9 countries.

Hans-Christoph Diener1 Department of Neurology, University Hospital Essen, Essen, Germany.
Cristina Tassorelli2 Headache Science Center, IRCCS Mondino Foundation, Pavia, Italy.
David W Dodick4 Department of Neurology, Mayo Clinic, Phoenix, AZ, USA.
Stephen D Silberstein5 Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA.
Richard B Lipton6 Montefiore Headache Center, Department of Neurology and Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Messoud Ashina7 Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark.
Werner J Becker8 Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Michel D Ferrari10 Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
Peter J Goadsby11 National Institute for Health Research Wellcome Trust King's Clinical Research Facility, King's College London, London, England.ORCID 0000-0003-3260-5904
Patricia Pozo-Rosich12 Headache Research Group, Vall d'Hebron Institute of Research, Universitat Autònoma de Barcelona, Barcelona, Spain.
Shuu-Jiun Wang13 Headache & Craniofacial Pain Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Jay Mandrekar15 Department of Health Sciences Research, Mayo Clinic Rochester, MN, USA.
International Headache Society Clinical Trials Standing Committee
Albert Einstein College of Medicine · USEssen University Hospital · DEKing's College London · GBLeiden University Medical Center · NLMayo Clinic Hospital · USMayo Clinic in Florida · USNational Yang Ming Chiao Tung University · TWThomas Jefferson University · USUniversitat Autònoma de Barcelona · ESUniversity of Calgary · CAUniversity of Copenhagen · DKUniversity of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The quality of clinical trials is an essential part of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for controlled trials of drugs in migraine. Scientific and clinical developments in headache medicine led to second and third editions in 2000 and 2012, respectively. The current, fourth edition of the Guidelines retains the structure and much content from previous editions. However, it also incorporates evidence from clinical trials published after the third edition as well as feedback from meetings with regulators, pharmaceutical and device manufacturers, and patient associations. Its final form reflects the collective expertise and judgement of the Committee. These updated recommendations and commentary are intended to meet the Society's continuing objective of providing a contemporary, standardized, and evidence-based approach to the conduct and reporting of randomised controlled trials for the acute treatment of migraine attacks.

Indexed as

AdultClinical Trials as TopicFemaleHumansMaleMigraine DisordersResearch Designacute treatment of migraine attacks in adultscontrolled trialsGuidelines

Identifiers

PMID30806518
PMCPMC6501455
OpenAlexW2918066963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.